Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

DPP-4 Inhibitor

Therapeutic area intelligence for DPP-4 Inhibitor with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 7

Companies

Ajanta Pharma →

AstraZeneca →

Biocon Pharma →

Biocon Pharma Ltd →

Dr. Reddy's Labs →

Assets

Linagliptin →

Sitagliptin →

Recent signals(7)

August 3, 2026

FDA Submission Overview for Sitagliptin by Biocon Pharma

Biocon Pharma Ltd has submitted an original application (ANDA218441) for Sitagliptin, currently under standard review.

CompetitiveJuly 24, 2026

FDA Accepts ANDA for Sitagliptin Phosphate by Dr. Reddy's Labs

The FDA has accepted the ANDA214700 application for Sitagliptin Phosphate from Dr. Reddy's Labs.

RegulatoryJuly 23, 2026

FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)

The FDA has approved a supplemental application for QTERN, a combination of dapagliflozin and saxagliptin.

RegulatoryJuly 23, 2026

FDA Accepts Supplement for STEGLUJAN (Ertugliflozin/Sitagliptin)

The FDA has accepted a supplemental application for STEGLUJAN, a combination of ertugliflozin and sitagliptin.

StrategyJuly 20, 2026

FDA Approval Application for Linagliptin by Teva Pharmaceuticals

Teva Pharmaceuticals has submitted an original application for Linagliptin under ANDA208433 with a standard review priority.

CompetitiveJuly 15, 2026

Ajanta Pharma submits ANDA for Sitagliptin and Metformin Hydrochloride

Ajanta Pharma has submitted an Abbreviated New Drug Application (ANDA) for Sitagliptin and Metformin Hydrochloride.

RegulatoryJuly 12, 2026

FDA Submission Update for Sitagliptin by Biocon Pharma

Biocon Pharma has submitted an original ANDA for Sitagliptin, currently under standard review.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.